Product Data Sheet

Calcium dobesilate

Cat. No.: HY-111603 CAS No.: 20123-80-2

Molecular Formula: $C_{12}H_{10}CaO_{10}S_{2}$

Molecular Weight: 418.41 Target: **Apoptosis**

Pathway: **Apoptosis**

Storage: 4°C, sealed storage, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

DMSO: 150 mg/mL (358.50 mM; Need ultrasonic)

 $H_2O : \ge 100 \text{ mg/mL} (239.00 \text{ mM})$

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3900 mL	11.9500 mL	23.9000 mL
	5 mM	0.4780 mL	2.3900 mL	4.7800 mL
	10 mM	0.2390 mL	1.1950 mL	2.3900 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.98 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.98 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.98 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Calcium dobesilate, a vasoprotective, is widely used in chronic venous disease, diabetic retinopathy and the symptoms of haemorrhoidal attack in many countries.

REFERENCES

1]. Allain H, et al. Safety of calciu	um dobesilate in chronic venous d	isease, diabetic retinopathy an	d haemorrhoids. Drug Saf. 2004;27(9):649-60.
	Continue Duradurat has madely	f	Januliaskiana Farrasanak usas	and.
			l applications. For research use	
		Fax: 609-228-5909 Park Dr, Suite Q, Monmouth	E-mail: tech@MedChemExpress Junction, NJ 08852, USA	s.com

Page 2 of 2 www.MedChemExpress.com